PDCD1 and hypophysitis: Although LAG-3 inhibitors have not been adequately studied with respect to hypophysitis risk, the addition of a LAG-3 inhibitor to a PD-1 inhibitor appears to raise the incidence of hypophysitis from 0.8% to 2.5% [3,23].